Elevated plasma F2-isoprostanes in patients on long-term hemodialysis

Elevated plasma F2-isoprostanes in patients on long-term hemodialysis Background End-stage renal disease (ESRD) patients on long-term hemodialysis (HD) may be under increased oxidative stress, caused by either HD or renal failure. Plasma F2-isoprostanes have been established as an important indicator of in vivo oxidative stress. Methods Plasma esterified F2-isoprostanes were measured in 25 HD patients and 23 controls with normal renal function, employing gas chromatography-mass spectrometry with negative chemical ionization (GC-MS-NCI). C-reactive protein (CRP) was determined concurrently in patients and controls by enzyme-linked immunosorbent assay (ELISA). α-Tocopherol, retinol, albumin and creatinine were also determined. Results The average total esterified F2-isoprostanes in the ESRD patients was 1.62 ± 0.73 vs. 0.27 ± 0.10 ng/mL in controls ( P P r = 0.48, P = 0.015). Plasma α-tocopherol did not differ between patients and controls, but plasma retinol was higher in patients (3.15 ± 1.71 μmol/L) than in controls (1.97 ± 0.51 μmol/L, P Conclusions These results are consistent with the hypothesis that oxidative stress in ESRD patients contributes to increased values of esterified plasma F2-isoprostanes, with concurrent increases in plasma CRP levels in some patients. Impaired clearance of esterified F2-isoprostanes may contribute to the elevated levels in renal failure. Plasma esterified F2-isoprostanes may be a useful indicator to evaluate effectiveness of interventions to decrease oxidative stress and associated inflammation.